BRBR

BellRing is a focused, asset-light branded play on convenient nutrition (Premier Protein, Dymatize) and the numbers show a business still firmly in growth mode: revenue compounded from $1.25B (FY2021) to $2.32B (FY2025), up 16.1% in the latest year, with Premier Protein sales +17% on 15% higher volume and Dymatize +13% on 23% volume — broad-based, volume-led demand, not just price. Because products are made by third-party contract manufacturers, capex is trivial ($4.7M) and operating cash flow rose 30.6% to $261M, implying free cash flow near $256M against a $1.48B market cap — a ~17% FCF yield. The FY2025 net-income decline (-12.3% to $216M) is almost entirely a non-operating, one-time item: the MD&A pins it to a $69.0M legal provision; back that out and operating profit would have risen rather than fallen 8%. At 7.4x earnings and 0.6x sales, the market is paying staple-in-decline multiples for a double-digit grower riding a structural protein/GLP-1 tailwind the company itself flags.

The balance sheet needs context but is not distress. Reported stockholders' equity is -$454M, which optically looks alarming, but it is a capital-return artifact: retained earnings are positive at $273M and the company bought back 5.2M shares at ~$40 in the September 2025 quarter under a $300M authorization, then approved a fresh $400M authorization through 2027. Buying stock above book value drives equity negative — this is shareholders being paid, not insolvency. The real constraint is $1.08B of long-term debt (up 30%) against $72M cash and $68.4M annual interest; operating profit still covers interest ~5x and OCF comfortably services it, but leverage near ~3x EBITDA limits the margin for error.